$NRXS
Neuraxis, INC Stock $nrxs

$nrxs Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223042163 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$531.5K	$477.5K	$0.00
YoY Change	-13.31%
Cost Of Revenue	$72.35K	$67.29K	$221.9K
YoY Change	-3.8%	-69.67%
Gross Profit	$459.1K	$410.2K	$1.850M
YoY Change	-14.64%	-77.83%
Gross Profit Margin	86.39%	85.91%
Selling, General & Admin	$2.085M	$3.388M	$4.092M
YoY Change	44.49%	-17.21%
% of Gross Profit	454.04%	825.89%	221.19%
Research & Development		$44.95K	$144.2K
YoY Change		-68.84%
% of Gross Profit		10.96%	7.8%
Depreciation & Amortization	$10.73K	$7.609K	$25.05K
YoY Change	-11.18%	-69.62%	-16.5%
% of Gross Profit	2.34%	1.86%	1.35%
Operating Expenses	$2.082M	$3.433M	$4.236M
YoY Change	36.63%	-18.96%
Operating Profit	-$1.623M	-$3.022M	-$2.386M
YoY Change	64.59%	26.67%
Interest Expense	-$24.65K	$102.6K	-$1.703M
YoY Change	-88.98%	-106.03%
% of Operating Profit
Other Income/Expense, Net	-$3.665M	-$1.882M	-$677.2K
YoY Change	-406.4%	177.91%
Pretax Income	-$5.313M	-$4.900M	-$4.766M
YoY Change	38882.47%	2.8%
Income Tax
% Of Pretax Income
Net Earnings	-$5.313M	-$4.904M	-$5.339M
YoY Change	2474.03%	-8.13%
Net Earnings / Revenue	-999.76%	-1027.18%
Basic Earnings Per Share		-$1.35	-$1.14
Diluted Earnings Per Share	-$1.01	-$1.35	-$0.87
COMMON SHARES
Basic Shares Outstanding	5.290M shares	4.981M shares	1.989M shares
Diluted Shares Outstanding		3.626M shares	1.989M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$78.56K	$760.0K	$7.820K
YoY Change	-69.03%	9618.67%
Cash & Equivalents	$78.56K	$761.2K	$7.820K
Short-Term Investments
Other Short-Term Assets	$69.66K	$40.00K	$16.15K
YoY Change	9442.47%	147.68%
Inventory	$21.22K	$34.53K	$57.32K
Prepaid Expenses
Receivables	$73.17K	$132.4K	$320.2K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$242.6K	$966.9K	$401.5K
YoY Change	-49.13%	140.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$88.55K	$80.33K	$203.4K
YoY Change	-53.24%	-60.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$694.5K
YoY Change	-100.0%	-100.0%
Total Long-Term Assets	$266.9K	$269.1K	$930.4K
YoY Change	-73.41%	-71.08%
TOTAL ASSETS
Total Short-Term Assets	$242.6K	$966.9K	$401.5K
Total Long-Term Assets	$266.9K	$269.1K	$930.4K
Total Assets	$509.5K	$1.236M	$1.332M
YoY Change	-65.59%	-7.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.204M	$566.6K	$1.450M
YoY Change	-24.36%	-60.93%
Accrued Expenses	$401.1K	$280.1K	$849.8K
YoY Change	-53.76%	-67.04%
Deferred Revenue
YoY Change
Short-Term Debt	$148.1K	$194.0K	$87.02K
YoY Change	-48.3%	122.94%
Long-Term Debt Due	$148.1K	$190.0K	$192.1K
YoY Change	-27.0%	-1.09%
Total Short-Term Liabilities	$1.886M	$2.258M	$6.757M
YoY Change	-72.98%	-66.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$51.69K
YoY Change		-100.0%
Other Long-Term Liabilities	$27.07K	$40.00K	$84.55K
YoY Change	-64.48%	-52.69%
Total Long-Term Liabilities	$27.07K	$39.35K	$136.2K
YoY Change	-64.47%	-71.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.886M	$2.258M	$6.757M
Total Long-Term Liabilities	$27.07K	$39.35K	$136.2K
Total Liabilities	$1.913M	$2.297M	$6.893M
YoY Change	-72.89%	-66.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$48.56M	-$43.24M
YoY Change	43.11%
Common Stock	$6.509K	$5.149K
YoY Change	231.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.403M	-$1.100M	-$5.561M
YoY Change
Total Liabilities & Shareholders Equity	$509.5K	$1.236M	$1.332M
YoY Change	-65.59%	-7.21%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$5.313M	-$4.904M	-$5.339M
YoY Change	2474.03%	-8.13%
Depreciation, Depletion And Amortization	$10.73K	$7.609K	$25.05K
YoY Change	-11.18%	-69.62%	-16.5%
Cash From Operating Activities	-$2.634M	-$2.810M	-$2.084M
YoY Change	1129.05%	34.86%	2.14%
INVESTING ACTIVITIES
Capital Expenditures	$11.78K	$50.00K	$11.39K
YoY Change	-76.35%	338.98%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$11.78K	-$50.00K	-$11.39K
YoY Change	-76.35%	338.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.600M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.961M	3.570M	1.782M
YoY Change	284.43%	100.33%	324.3%
NET CHANGE
Cash From Operating Activities	-2.634M	-2.810M	-2.084M
Cash From Investing Activities	-11.78K	-50.00K	-11.39K
Cash From Financing Activities	1.961M	3.570M	1.782M
Net Change In Cash	-685.1K	710.0K	-313.0K
YoY Change	-378.65%	-326.81%	-80.68%
FREE CASH FLOW
Cash From Operating Activities	-$2.634M	-$2.810M	-$2.084M
Capital Expenditures	$11.78K	$50.00K	$11.39K
Free Cash Flow	-$2.646M	-$2.860M	-$2.095M
YoY Change	901.69%	36.51%	2.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001933567
CY2023Q3	us-gaap	Deferred Costs DeferredCosts		usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q4	NRXS	Share Liabilities Current ShareLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome		usd
	us-gaap	Interest And Other Income InterestAndOtherIncome		usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2022Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	NRXS	Noncash Interest Expense NoncashInterestExpense		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	NRXS	Issuance Of Common Stock For Noncash Consideration IssuanceOfCommonStockForNoncashConsideration		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	NRXS	Relative Fair Value Of Shares Issued With Convertible Notes RelativeFairValueOfSharesIssuedWithConvertibleNotes		usd
	NRXS	Deferred Offering Costs In Accounts Payable DeferredOfferingCostsInAccountsPayable		usd
CY2023Q3	us-gaap	Deferred Costs DeferredCosts		usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q3	us-gaap	Loans Payable LoansPayable		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2022Q4	NRXS	Accrued Board Fess AccruedBoardFess		usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent		usd
CY2023Q3	NRXS	Related Party Interest Payable Current RelatedPartyInterestPayableCurrent		usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2022Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41775
	dei	Entity Registrant Name EntityRegistrantName	NEURAXIS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5079684
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11550 N. Meridian Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 325
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
	dei	City Area Code CityAreaCode	(812)
	dei	Local Phone Number LocalPhoneNumber	689-0791
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	NRXS
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5289514	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	761249	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	253699	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	132382	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	174399	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	34530	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	48133	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	38693	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	726	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	966854	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	476957	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	420586	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	405845	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	340260	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	317834	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80326	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88011	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	736736	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	78043	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	101382	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	110695	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77558	usd
CY2023Q3	us-gaap	Assets Assets	1235918	usd
CY2022Q4	us-gaap	Assets Assets	1480644	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	566649	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1592116	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	280063	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	834062	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45194	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	33395	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	0	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	3327213	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	228342	usd
CY2023Q3	us-gaap	Deposits Deposits	68972	usd
CY2022Q4	us-gaap	Deposits Deposits	59174	usd
CY2023Q3	NRXS	Share Liabilities Current ShareLiabilitiesCurrent	934256	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1735700	usd
CY2023Q3	NRXS	Warrant Liabilities WarrantLiabilities	168269	usd
CY2022Q4	NRXS	Warrant Liabilities WarrantLiabilities	2234384	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2257652	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6978058	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39353	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76199	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	39353	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	76199	usd
CY2023Q3	us-gaap	Liabilities Liabilities	2297005	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7054257	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5149340	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5149340	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1963322	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1963322	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	5149	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1963	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42178570	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28355230	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43244806	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33931428	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1061087	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5573613	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1235918	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1480644	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	477460	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	618805	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1928590	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2071653	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	67287	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	67638	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	231000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	221846	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	410173	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	551167	usd
	us-gaap	Gross Profit GrossProfit	1697590	usd
	us-gaap	Gross Profit GrossProfit	1849807	usd
CY2023Q3	us-gaap	Selling Expense SellingExpense	64210	usd
CY2022Q3	us-gaap	Selling Expense SellingExpense	81589	usd
	us-gaap	Selling Expense SellingExpense	250933	usd
	us-gaap	Selling Expense SellingExpense	344892	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44950	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86175	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	171536	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	144239	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3323352	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1586527	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6316411	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3746688	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3022339	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1203124	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5041290	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2386012	usd
CY2022Q3	NRXS	Financing Charges FinancingCharges	601128	usd
	NRXS	Financing Charges FinancingCharges	2772	usd
	NRXS	Financing Charges FinancingCharges	1473892	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	102628	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	100741	usd
	us-gaap	Interest Expense InterestExpense	453869	usd
	us-gaap	Interest Expense InterestExpense	161291	usd
CY2023Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	2103	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	2103	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-592853	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	90628	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-791610	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	660189	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6394	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-68032	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	198551	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-68032	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1331030	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	16029	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4881622	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	28973	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1058062	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	71436	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	9931	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11483	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11956	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1578	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9008	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1882017	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-876558	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4272088	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2380421	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-4904356	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2079682	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9313378	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4766433	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.65
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.65
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.70
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3625519	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3625519	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1988758	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1988758	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2552007	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2552007	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1976380	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1976380	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-825660	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11994	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1170221	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1983887	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12127	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1048	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1516530	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3487242	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3198	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2317	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2079682	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-5561409	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5573613	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2173408	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-7747021	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2235614	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-9982635	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-9982635	usd
CY2023Q3	NRXS	Stock Issued During Period Value Common Stock Issued Upon Initial Public Offering StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering	4860721	usd
CY2023Q3	NRXS	Stock Issued During Period Value Common Stock Issued Upon Preferred Stock Conversion StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion	-1076	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	8966259	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-4904356	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1061087	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1061087	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9313378	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4766433	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4881622	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	28973	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	30290	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25047	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6380	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	42795	usd
	NRXS	Noncash Lease Expense NoncashLeaseExpense	23339	usd
	NRXS	Noncash Lease Expense NoncashLeaseExpense	19945	usd
	NRXS	Noncash Interest Expense NoncashInterestExpense	260777	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27319	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	71436	usd
	NRXS	Issuance Of Common Stock For Noncash Consideration IssuanceOfCommonStockForNoncashConsideration	2550000	usd
	NRXS	Finance Charges FinanceCharges	2772	usd
	NRXS	Finance Charges FinanceCharges	1473892	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	198551	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-68032	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-791610	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	660189	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-35637	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	247738	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-13603	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	18141	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	37967	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	481	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1025467	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	359652	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-415181	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	256184	usd
	NRXS	Increase Decrease In Customer Deposit IncreaseDecreaseInCustomerDeposit	9798	usd
	NRXS	Increase Decrease In Customer Deposit IncreaseDecreaseInCustomerDeposit	7762	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-25047	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-20686	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4064419	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2083689	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14741	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11390	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	41000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-55741	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11390	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5464642	usd
	NRXS	Offering Costs In Advance Of Sale Of Common Stock OfferingCostsInAdvanceOfSaleOfCommonStock	-2417185	usd
	NRXS	Offering Costs In Advance Of Sale Of Common Stock OfferingCostsInAdvanceOfSaleOfCommonStock	-87694	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3487578	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	122265	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	159831	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	122000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4908000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1870000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4627710	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1782041	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	507550	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-313038	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	253699	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	320858	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	761249	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7820	usd
	us-gaap	Interest Paid Net InterestPaidNet	192015	usd
	us-gaap	Interest Paid Net InterestPaidNet	118391	usd
	NRXS	Fair Value Of Warrant Liabilities Of Warrants From Convertible Notes FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes	2446502	usd
	NRXS	Fair Value Of Warrant Liabilities Of Warrants From Convertible Notes FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes	1822435	usd
	NRXS	Fair Value Of Derivative Liabilities Of Conversion Feature From Convertible Notes FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes	2375378	usd
	NRXS	Fair Value Of Derivative Liabilities Of Conversion Feature From Convertible Notes FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes	1518092	usd
	NRXS	Relative Fair Value Of Shares Issued With Convertible Notes RelativeFairValueOfSharesIssuedWithConvertibleNotes	3365	usd
	NRXS	Deferred Offering Costs In Accounts Payable DeferredOfferingCostsInAccountsPayable	606830	usd
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	4-for-1 stock split
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2700000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	13400000	shares
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2 reverse stock split
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1120000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zsJMpCNDGTGg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_ze6mOwZS3PQh">Use of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for doubtful accounts, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of intellectual property. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24895	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	31275	usd
CY2023Q3	NRXS	Allowance For Credit Losses AllowanceForCreditLosses	9996	usd
	NRXS	Allowance For Credit Losses AllowanceForCreditLosses	13923	usd
CY2022Q3	NRXS	Allowance For Credit Losses AllowanceForCreditLosses	13216	usd
	NRXS	Allowance For Credit Losses AllowanceForCreditLosses	42795	usd
CY2023Q3	us-gaap	Deposits Deposits	68972	usd
CY2022Q4	us-gaap	Deposits Deposits	59174	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	736736	usd
CY2023Q3	us-gaap	Depreciation Depreciation	7609	usd
	us-gaap	Depreciation Depreciation	22426	usd
CY2022Q3	us-gaap	Depreciation Depreciation	7868	usd
	us-gaap	Depreciation Depreciation	23592	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2621	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7864	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1455	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.65
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.65
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	21730	usd
	us-gaap	Advertising Expense AdvertisingExpense	54716	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	3300	usd
	us-gaap	Advertising Expense AdvertisingExpense	14900	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.70
	us-gaap	Depreciation Depreciation	22426	usd
	us-gaap	Depreciation Depreciation	23592	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	40000	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2190102	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3107406	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3349913	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-4904356	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2079682	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9313378	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4766433	usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-192794	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-572098	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4904356	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2272476	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9313378	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5338531	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3625519	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3625519	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1988758	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1988758	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2552007	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2552007	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1976380	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1976380	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2023Q3	us-gaap	Revenues Revenues	477460	usd
CY2022Q3	us-gaap	Revenues Revenues	618805	usd
	us-gaap	Revenues Revenues	1928590	usd
	us-gaap	Revenues Revenues	2071653	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	115301	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	174399	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	132382	usd
CY2023Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	317834	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80326	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88011	usd
CY2023Q3	us-gaap	Depreciation Depreciation	7609	usd
CY2022Q3	us-gaap	Depreciation Depreciation	7868	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zM0Gk3NboIUe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zKWKqXQo8tsf">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the country.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables consist of unsecured amounts due from customers. As of September 30, 2023, accounts receivable from two customers with balances due in excess of <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1L1HG4h2jS7" title="Risk percentage">10</span>% of total accounts receivable were approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBD1Sj83No51" title="Risk percentage">15</span>%, and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKpltLal5Aie" title="Risk percentage">14</span>%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zAo4NXjPikR4" title="Risk percentage">10</span>% of total accounts receivable was <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHyPJRUJUNE1" title="Risk percentage">23</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zseEXKVcZKGk" title="Risk percentage">15</span>%, and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6dudvvOj559" title="Risk percentage">12</span>%, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below sets forth the Company’s customers that accounted for greater than <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z9ct5uTYbwOd" title="Risk percentage">10</span>% of its revenues for the three months ended September 30, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zYy9OxN8ttuh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zyAfbN1c6Uzh">Schedule of Customers Accounted Revenues</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage<br/> of Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage<br/> of Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEvX0D5nhpV8" style="width: 11%; font-weight: bold; text-align: right" title="Revenue">96,820</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuS3LIZvdlVi" title="Risk percentage">20</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSpUv9JKtZEe" style="width: 11%; text-align: right" title="Revenue">60,520</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEHx0yfeqJH1" title="Risk percentage">10</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Hospital B</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIO3g0RbRSFg" style="font-weight: bold; text-align: right" title="Revenue">123,800</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zutmLh2NyY7k" title="Risk percentage">26</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMTBk9Qs8opd" style="text-align: right" title="Revenue">119,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5jRXVCL8qt4" title="Risk percentage">19</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Hospital C</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zm8eUsPaBfl1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">18,450</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNZrmq7V9XP5" title="Risk percentage">4</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNMPgcONUdMl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">74,425</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuoneHYXp86d" title="Risk percentage">12</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zrrdyOd0wrCd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">239,070</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6ojZ3BmXIM9" title="Risk percentage">50</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKeD9SEx1MX8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">254,445</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzeb7oiLSMe6" title="Risk percentage">41</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below sets forth the Company’s customers that accounted for greater than <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z9IsGs2T3m2a" title="Risk percentage">10</span>% of its revenues for the nine months ended September 30, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage<br/> of Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage<br/> of Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zrQYKLMhXWHa" style="width: 11%; font-weight: bold; text-align: right" title="Revenue">388,240</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCo3i8ZHi1j3" title="Risk percentage">20</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zBNRoFepIGVb" style="width: 11%; text-align: right" title="Revenue">248,725</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWncPvMB8x61" title="Risk percentage">12</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Hospital B</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPnDGn11CZGk" style="font-weight: bold; text-align: right" title="Revenue">246,400</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmWXJSeu8qfk" title="Risk percentage">13</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zYH1WXmW8WDc" style="text-align: right" title="Revenue">359,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmiMoDK1ARxd" title="Risk percentage">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Hospital C</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRzxDLO4babf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">193,000</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmzVDB7L4uh2" title="Risk percentage">10</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzKm50Qskw74" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">441,125</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3DWkp3pKMgf" title="Risk percentage">22</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znbCs7q31A12" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">827,640</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z4phFcGZdOS6" title="Risk percentage">43</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zy7chcDL0xod" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">1,049,650</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCxKaV5Af8Qi" title="Risk percentage">51</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A9_zVXKhVaR2HV3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company’s bank balances may exceed the FDIC limit of $<span id="xdx_906_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zyOd6TijkU9l" title="Cash, FDIC insured amount">250,000</span>; however, management does not feel that this has a material impact on the financial condition. At September 30, 2023 and December 31, 2022, the Company’s uninsured cash balances totaled $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_c20230930_zsC9NW6QwpPg" title="Cash, uninsured amount">261,239</span>, and $<span id="xdx_90E_eus-gaap--CashUninsuredAmount_iI_c20221231_znjaqRCfzWxf" title="Cash, uninsured amount">0</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	261239	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1100000	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	194000	usd
CY2023Q3	us-gaap	Cash Cash	761000	usd
CY2023Q3	NRXS	Working Capital Deficit WorkingCapitalDeficit	1300000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6600000	usd
CY2023Q3	NRXS	Allowance For Interest Receivable Current AllowanceForInterestReceivableCurrent	1141441	usd
CY2023Q3	NRXS	Interest And Service Fee Accrued InterestAndServiceFeeAccrued	66648	usd
	us-gaap	Interest Paid InterestPaid	37103	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	58051	usd
CY2022Q4	NRXS	Interest And Service Fee Accrued InterestAndServiceFeeAccrued	98290	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	420586	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	405845	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	340260	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	133279	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	92278	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	22584	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14720	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	110695	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77558	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2621	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7864	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1455	usd
CY2023Q3	NRXS	Accrued Wages Current AccruedWagesCurrent	60432	usd
CY2022Q4	NRXS	Accrued Wages Current AccruedWagesCurrent	523003	usd
CY2023Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	20213	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	16555	usd
CY2023Q3	NRXS	Accrued Board Fess AccruedBoardFess	48345	usd
CY2023Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	86384	usd
CY2023Q3	NRXS	Capital Raise Fees CapitalRaiseFees	-3250	usd
CY2022Q4	NRXS	Capital Raise Fees CapitalRaiseFees	88259	usd
CY2023Q3	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	1291	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	777	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	66648	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	173826	usd
CY2022Q4	NRXS	Related Party Interest Payable Current RelatedPartyInterestPayableCurrent	31642	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	280063	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	834062	usd
CY2023Q3	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	46187	usd
CY2023Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	4825067	usd
CY2023Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	5254834	usd
CY2022Q4	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2324988	usd
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	Two of the leases in Versailles started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments for these leases are $550 and $1,600 with a 3% per annum increase starting with the optional five-year term. The lease in Carmel started March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment started at $1,472 with an annual increase of approximately 2.7%. On December 16, 2020, the Company entered into an amendment of the Carmel lease that extended the initial term by two years
	us-gaap	Operating Lease Payments OperatingLeasePayments	550	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1600	usd
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.03	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	1472	usd
CY2023Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.027	pure
	us-gaap	Operating Lease Expense OperatingLeaseExpense	35678	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	47571	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	78043	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	101382	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	45194	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33395	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39353	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76199	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	84547	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	109594	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.150	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.150	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	9986	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	27072	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	22316	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	26810	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	86184	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1637	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	84547	usd
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	4-for-1 stock split
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2700000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	13400000	shares
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	2-for-1 reverse stock split
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1828012	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1120000	shares
	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	0.80	pure
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	1076242	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1319394	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y10D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.94
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2023Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	1231772	shares
CY2023Q3	NRXS	Common Stock Capital Unissued Value CommonStockCapitalUnissuedValue	934256	usd
CY2023Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	1231772	shares
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03	pure
	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	3657	usd
	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	13058	usd
CY2019Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000	usd
	us-gaap	Health Care Organization Stop Loss Insurance Premium Expense HealthCareOrganizationStopLossInsurancePremiumExpense	175616	usd
	us-gaap	Health Care Organization Stop Loss Insurance Premium Expense HealthCareOrganizationStopLossInsurancePremiumExpense	136428	usd
	NRXS	Health Care Organization Stop Loss Insurance Premium Percentage HealthCareOrganizationStopLossInsurancePremiumPercentage	0.485	pure
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-23-042163-index-headers.html	Edgar Link	pending
0001493152-23-042163-index.html	Edgar Link	pending
0001493152-23-042163.txt	Edgar Link	pending
0001493152-23-042163-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nrxs-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nrxs-20230930_cal.xml	Edgar Link	unprocessable
nrxs-20230930_def.xml	Edgar Link	unprocessable
nrxs-20230930_pre.xml	Edgar Link	unprocessable
nrxs-20230930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NRXS
Neuraxis, INC Stock $nrxs

2023 Q4 Form 10-Q Financial Statement

#000149315223042163 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXS Neuraxis, INC Stock $nrxs

2023 Q4 Form 10-Q Financial Statement

#000149315223042163 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXS
Neuraxis, INC Stock $nrxs